The U.S. Food and Drug Administration (FDA) has approved a self-injected version of Saphnelo (anifrolumab-fnia). Like the original version of Saphnelo, which is given by infusion into the bloodstream every four weeks, the Saphnelo Pen is indicated for use in combination with standard therapy for systemic lupus erythematosus…